Salicylic acid plant ramp-up delays
The salicylic acid plant is still in stabilization; delays in achieving 800 tons/month breakeven could pressure margins.
high · management_commentaryAarti Drugs Limited — Q2 FY26
Aarti Drugs reported a solid Q2 FY26 with consolidated revenue of ₹652.9 crore (+9% YoY) and EBITDA of ₹84.4 crore (+23% YoY), driven by robust export volume growth of over 30%...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Domestic antibiotic demand weakness
Domestic demand, especially in antibiotics, remained soft with slight degrowth; recovery expected only from Q4.
medium · management_commentaryPricing pressure on methylamines
Management acknowledged potential price erosion as new methylamine capacity comes online, which could impact margins.
medium · analyst_questionTarapur plant closure risk
Voluntary closure of chlorosulfonation process at Tarapur due to gas leak; though no material impact currently, regulatory delays could affect operations.
low · management_commentary